CHUGAI PHARMACEUTICAL CO.,LTD.
Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS)
Filed with TSE ·
Watch Chugai Pharmaceutical's latest callChugai Pharmaceutical (Tokyo:4519) Q2 2026 Earnings Call · Replay · Jul 24Read the transcript of Chugai Pharmaceutical (Tokyo:4519) Q2 2026 Earnings Call6ix is reading this filing.
View original source (TDnet)Chugai Pharmaceutical Co., Ltd. on 6ix
In the deck
Story so far
Earlier from Chugai Pharmaceutical
- F. Hoffmann-La Roche Announces Third Quarter Sales 2026
- Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA
- Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
- Chugai and GSK Sign Exclusive License Agreement for Anti-Dengue Virus Antibody AID351
- Chugai Announces 2026 2nd Quarter Results
Follow Chugai Pharmaceutical into a list and get an email when it puts out news.
Follow Chugai Pharmaceutical